These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26746842)

  • 21. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of cytopathological specimens and an automated image analysis for the evaluation of HER2 status and intratumor heterogeneity in breast carcinoma.
    Arihiro K; Oda M; Ogawa K; Kaneko Y; Shimizu T; Tanaka Y; Marubashi Y; Ishida K; Takai C; Taoka C; Kimura S; Shiroma N
    Pathol Res Pract; 2016 Dec; 212(12):1126-1132. PubMed ID: 27712974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples.
    Kinsella MD; Birdsong GG; Siddiqui MT; Cohen C; Hanley KZ
    Diagn Cytopathol; 2013 Mar; 41(3):192-8. PubMed ID: 22611048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
    Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
    Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of fluorescence in-situ hybridisation with dual-colour in-situ hybridisation for assessment of HER2 gene amplification of breast cancer in Hong Kong.
    Tang SM; Soong IS; Luk MY; Suen DT; Hioe F; Man EP; Tsun OK; Khoo US
    Hong Kong Med J; 2016 Apr; 22(2):144-51. PubMed ID: 26823385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines.
    O'Grady A; Allen D; Happerfield L; Johnson N; Provenzano E; Pinder SE; Tee L; Gu M; Kay EW
    Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):489-93. PubMed ID: 20661132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Impact of 2013 American Society of Clinical Oncology/College of American Pathologist guidelines on borderline immunostaining results for HER2: a retrospective study on HER2 FISH results in 1 780 cases of invasive breast cancers].
    Xu Y; Bai QM; Yang F; Zhu XL; Lu YM; Zhang J; Yang WT; Zhou XY
    Zhonghua Bing Li Xue Za Zhi; 2016 Aug; 45(8):545-9. PubMed ID: 27510780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment.
    Polónia A; Leitão D; Schmitt F
    Virchows Arch; 2016 Apr; 468(4):417-23. PubMed ID: 26754674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations.
    Hanna WM; Slodkowska E; Lu FI; Nafisi H; Nofech-Mozes S
    J Clin Oncol; 2017 Sep; 35(26):3039-3045. PubMed ID: 28445098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
    Wolff AC; Hammond MEH; Allison KH; Harvey BE; Mangu PB; Bartlett JMS; Bilous M; Ellis IO; Fitzgibbons P; Hanna W; Jenkins RB; Press MF; Spears PA; Vance GH; Viale G; McShane LM; Dowsett M
    J Clin Oncol; 2018 Jul; 36(20):2105-2122. PubMed ID: 29846122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).
    Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY
    Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists.
    Carbone A; Botti G; Gloghini A; Simone G; Truini M; Curcio MP; Gasparini P; Mangia A; Perin T; Salvi S; Testi A; Verderio P
    J Mol Diagn; 2008 Nov; 10(6):527-36. PubMed ID: 18832456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slide.
    Chenard MP; Wissler MP; Weingertner N; Mathelin C; Bellocq JP
    Virchows Arch; 2015 Aug; 467(2):169-75. PubMed ID: 25985875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Performance of Breast Cancer Human Epidermal Growth Factor Receptor 2 Fluorescence In Situ Hybridization and Brightfield In Situ Hybridization on College of American Pathologists Proficiency Tests.
    Geiersbach KB; Bridge JA; Dolan M; Jennings LJ; Persons DL; Souers RJ; Tsuchiya KD; Vasalos PH; Moncur JT
    Arch Pathol Lab Med; 2018 Oct; 142(10):1254-1259. PubMed ID: 29733681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer.
    Xu B; Shen J; Guo W; Zhao W; Zhuang Y; Wang L
    Pathol Res Pract; 2019 Feb; 215(2):251-255. PubMed ID: 30420102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunocytochemical results for HER2 and Ki67 in breast cancer touch-smear cell specimens are reliable.
    Morimoto M; Bando Y; Nakagawa M; Takechi H; Yoshida T; Honda J; Tadokoro Y; Moriya T; Sasa M; Tangoku A
    Breast Cancer; 2016 Jul; 23(4):577-82. PubMed ID: 25808597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
    van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
    Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2 in situ hybridization test in breast cancer: quantifying margins of error and genetic heterogeneity.
    Polónia A; Caramelo A
    Mod Pathol; 2021 Aug; 34(8):1478-1486. PubMed ID: 33980971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updated UK Recommendations for HER2 assessment in breast cancer.
    Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
    J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.